Decoding hypervirulence in carbapenem-resistant Klebsiella pneumoniae: genomic and phenotypic profiling reveals capsular polysaccharide as a key driver of pathogenicity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41662361.
- Also identified by DOI 10.1093/infdis/jiag075.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The global dissemination of hypervirulent carbapenem-resistant Klebsiella pneumoniae (hv-CRKP) poses escalating threats to public health. Substantial controversy persists regarding its true virulence potential, highlighting the need for reliable biomarkers to enable early diagnosis and targeted therapy. Using a mouse subcutaneous challenge model, we characterized 59 carbapenem-resistant K. pneumoniae (CRKP) isolates, identifying 37.29% (22/59) as convergent hv-CRKP. Phenotypic and genotypic characterization, integrated with genome-wide association study (GWAS) and transcriptomic analysis, was performed, and reliable biomarkers for accurate hv-CRKP detection were identified. Patients infected with hv-CRKP exhibited significantly higher sepsis incidence (P = 0.028) and increased mortality. Capsule production and hypermucoviscosity robustly discriminated hv-CRKP from CRKP. GWAS identified a significant association between an SNP in the rbtT locus and the hypervirulent phenotype, whereas virulence plasmid-associated genes showed no significant association. These findings suggest chromosomally encoded factors-independent of plasmid-borne elements-contribute critically to hypervirulence. Transcriptomics revealed rcsA-mediated capsule upregulation enhances macrophage phagocytosis resistance and bacterial survival, revealing a pivotal pathogenic mechanism. Both multivariable logistic regression and LASSO regression confirmed capsule production and rcsA expression as independent and robust diagnostic biomarkers to accurately assess virulence potential in carbapenem-resistant strains. We conclude that clinical application of the term "hv-CRKP" requires prudent validation and emphasize the urgency of developing biomarkers to precisely identify truly hypervirulent CRKP strains.